- Home
- TNDM vs KNSA Comparison
TNDM vs KNSA Comparison
Compare TNDM & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNDM
- KNSA
- Stock Information
- Founded
- TNDM 2006
- KNSA 2015
- Country
- TNDM United States
- KNSA United Kingdom
- Employees
- TNDM N/A
- KNSA N/A
- Industry
- TNDM Medical/Dental Instruments
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- TNDM Health Care
- KNSA Health Care
- Exchange
- TNDM Nasdaq
- KNSA Nasdaq
- Market Cap
- TNDM 1.9B
- KNSA 1.7B
- IPO Year
- TNDM 2013
- KNSA 2018
- Fundamental
- Price
- TNDM $27.34
- KNSA $21.29
- Analyst Decision
- TNDM Buy
- KNSA Strong Buy
- Analyst Count
- TNDM 16
- KNSA 5
- Target Price
- TNDM $52.50
- KNSA $36.60
- AVG Volume (30 Days)
- TNDM 1.6M
- KNSA 355.3K
- Earning Date
- TNDM 11-06-2024
- KNSA 10-29-2024
- Dividend Yield
- TNDM N/A
- KNSA N/A
- EPS Growth
- TNDM N/A
- KNSA N/A
- EPS
- TNDM N/A
- KNSA N/A
- Revenue
- TNDM $854,351,000.00
- KNSA $384,098,000.00
- Revenue This Year
- TNDM $23.61
- KNSA $60.05
- Revenue Next Year
- TNDM $10.79
- KNSA $36.32
- P/E Ratio
- TNDM N/A
- KNSA N/A
- Revenue Growth
- TNDM 10.75
- KNSA 54.41
- 52 Week Low
- TNDM $17.33
- KNSA $15.51
- 52 Week High
- TNDM $53.69
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- TNDM 26.79
- KNSA 32.46
- Support Level
- TNDM $29.90
- KNSA $22.62
- Resistance Level
- TNDM $35.50
- KNSA $23.34
- Average True Range (ATR)
- TNDM 1.79
- KNSA 1.18
- MACD
- TNDM -0.18
- KNSA -0.19
- Stochastic Oscillator
- TNDM 0.73
- KNSA 20.27
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.